
Asco 2022 – PMV’s therapeutic window slams shut
Liver and other toxicities threaten to scupper another attempt to reactivate mutated p53, the “guardian of the genome”.

Asco 2022 – Adicet works hard to avoid the allo Car-T scenario
Long-awaited gamma-delta Car-T data sees the response rate fall to 20% at six months, but when is a relapse not a relapse?

Asco 2022 – the spirit of Rova-T struggles to live on
DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.

Asco 2022 – Enhertu asks, how low can you go?
Another strong readout could redefine how Her2-negative breast cancer is treated, though a declared victory in triple-negatives is less clear.

Asco 2022 – investors clutch at the Tigit straws
Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.

Asco 2022 – Carvykti casts a long shadow
Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.